## **DEAV2002/0050 US NP**

R5 is H, F, Cl, Br,  $(C_1-C_6)$ -alkyl,  $CF_3$ ,  $OCF_3$ ,  $NO_2$ , CN,  $O-(C_1-C_6)$ -alkyl,  $CO-(C_1-C_6)$ -alkyl,  $(C_0-C_6)$ -alkylene-COO-( $C_1-C_6$ )-alkyl or  $SO_2-(C_1-C_6)$ -alkyl;

A is H, F, Cl, Br,  $(C_1-C_6)$ -alkyl,  $CF_3$ ,  $OCF_3$ ,  $NO_2$ , CN,  $O-(C_1-C_6)$ -alkyl,  $CO-(C_1-C_6)$ -alkyl,  $(C_0-C_6)$ -alkylene-COOH,  $(C_0-C_6)$ -alkyl or  $SO_2-(C_1-C_6)$ -alkyl;

is H,  $(C_1-C_6)$ -alkyl,  $(C_0-C_6)$ -alkylene-aryl, O- $(C_1-C_6)$ -alkyl, O- $(C_2-C_6)$ -alkenyl or O- $(C_2-C_6)$ -alkynyl, wherein said  $(C_1-C_6)$ -alkyl,  $(C_0-C_6)$ -alkylene-aryl, O- $(C_1-C_6)$ -alkyl, O- $(C_2-C_6)$ -alkenyl and O- $(C_2-C_6)$ -alkynyl are optionally mono- or polysubstituted by F, Cl or Br;

R8 is -(C=O)-X;

X is OH, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, NH<sub>2</sub>, NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl or N-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>;

m is 1 or 2; and

n is 1 or 2;

and pharmaceutically acceptable salts thereof.